Skip to content

Clinical Trial to evaluate the effects of Dibosudha tablet and Diabosudha Liquid Diabetes Mellitus type 2.

An Open Label, Single arm, prospective, Clinical study to evaluate efficacy and safety of Diabosudha Tablet and Diabosudha Liquid in Subjects with Mild to Moderate Diabetes Mellites Type 2.

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/047116
Enrollment
30
Registered
2022-11-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Sahyadri Ayurvedic Life Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gender: Either male or non-pregnant, non-lactating female aged > 18-70 2. Type 2 diabetes subjects (diagnosed clinically) = 6 months prior to screening. 3. HbA1c = 7.0 % and = 10.0 % (both inclusive). 4. Subjects willing to give written informed consent. 5. Subjects able to comply with the study protocol. 6. Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 7. Are willing to avoid participation in any other interventional clinical trial for the duration of this study.

Exclusion criteria

Exclusion criteria: 1. Suspected or confirmed pregnancy. 2. Diagnosis of any known chronic or acute medical disease of any kind (e.g., cardiovascular disease, respiratory disease, influenza, pneumonia, etc.) 3. Diagnosis of any known neurological disease or psychological disorder of any kind (e.g., brain lesion, epilepsy, anxiety, eating disorder, mood disorder, sleep disorder, etc.) 4. Any implanted electrical medical device (e.g., pacemaker, insulin pump, deep brain stimulator, etc.) 5. Any form of prescription medication. 6. Use of antibiotics in the three months prior to enrolment. 7. A direct or familiar relationship with the Sponsor, Investigator, or site personnel affiliated with the study.

Design outcomes

Primary

MeasureTime frame
•Change in level of HbA1c from baselineTimepoint: Day 0 To Day 90

Secondary

MeasureTime frame
• Change in BSL valuesTimepoint: Day 0 To Day 90;• Change in lipid panel test valuesTimepoint: Day 0 To Day 90;• Change in patient reported outcome for weight increase/ decrease, hunger and thirst and frequent urination at various follow up appointmentsTimepoint: Day 0 To Day 90

Countries

India

Contacts

Public ContactDr Shailesh Malekar

Alchemy Clinical Research Services

drabhijit@alchemyclinical.in9822371703

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026